Log In Sign up
The largest database of trusted experimental protocols

Crizotinib

Manufactured by Chemietek
Visit Supplier
Sourced in United States

Crizotinib is a pharmaceutical compound used as a laboratory reagent. It is a small-molecule tyrosine kinase inhibitor that targets the ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) proteins. Crizotinib is commonly used in research applications to study cell signaling pathways and their modulation.

Automatically generated - may contain errors

Lab products found in correlation

Lapatinib, by Selleck Chemicals (2 mentions) Ldk378, by Selleck Chemicals (2 mentions) Aew541, by Selleck Chemicals (2 mentions) Mab391, by R&D Systems (2 mentions) Osi 906, by Selleck Chemicals (2 mentions) Ceritinib, by Chemietek (1 mentions) Paclitaxel, by Chemietek (1 mentions) Etoposide, by Chemietek (1 mentions) Alectinib, by Chemietek (1 mentions) Basal medium eagle, by Thermo Fisher Scientific (1 mentions) Hepatocyte growth factor (hgf), by R&D Systems (1 mentions) Vandetanib, by Selleck Chemicals (1 mentions) Cabozantinib, by Selleck Chemicals (1 mentions) Sunitinib, by Chemietek (1 mentions) Imatinib, by Chemietek (1 mentions) Cabozantinib, by Chemietek (1 mentions) Matrigel matrix growth factor reduced, by BD (1 mentions) C57bl 6j b6 mice, by Jackson ImmunoResearch (1 mentions) Imatinib, by LC Laboratories (1 mentions) Crizotinib, by LC Laboratories (1 mentions)

6 protocols using crizotinib

1

Anticancer Compound Acquisition Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Crizotinib, alectinib, ceritinib, paclitaxel, pemetrexed, etoposide, luminespib (AUY922) and lorlatinib (PF-06463922) were purchased from ChemieTek (Indianapolis, IN). Ganetispib was purchased from Selleckchem (Houston, TX). Retaspimycin hydrochloride (IPI504) was purchased from Apexbio (Houston, TX).
Dhawan A., Nichol D., Kinose F., Abazeed M.E., Marusyk A., Haura E.B, & Scott J.G. (2017). Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer. Scientific Reports, 7, 1232.
+ Open protocol
+ Expand
2

NSCLC Cell Line Establishment and Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
NSCLC cell lines 201T and 273T were established in our laboratory from primary tissue and maintained at 37°C in 5% CO2.17 (link) All cells were grown in Basal Medium Eagle (BME) (Invitrogen Life Technologies, Inc.) with 10% fetal bovine serum (FBS) and 2mM L-glutamine. All cell lines were validated by genotyping within 2 months of conducting the experiments. Crizotinib was purchased from ChemieTek (Indianapolis, IN). Celecoxib in capsule form was obtained from the University of Pittsburgh Cancer Institute Pharmacy. Celecoxib was dissolved in DMSO and the molarity of the stock solution was adjusted based on the pharmaceutical formulation. HGF was purchased from R&D Systems (Minneapolis, MN).
Stabile L.P., Rothstein M.E., Gubish C.T., Cunningham D.E., Lee N, & Siegfried J.M. (2014). Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 9(9), 1285-1293.
+ Open protocol
+ Expand
3

Preparation and Dissolution of Kinase Inhibitors

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
X-376 was prepared as described previously14 (link). Crizotinib (ChemieTek, Indianapolis, IN, USA), OSI-906 (Selleck Chemicals, Houston, TX, USA), AEW-541 (Selleck Chemicals, Houston, TX, USA), LDK-378 (Selleck Chemicals, Houston, TX, USA) and Lapatinib (Selleck Chemicals, Houston, TX, USA) were dissolved in DMSO. Erlotinib was synthesized by the Memorial Sloan-Kettering Cancer Center (MSKCC) Organic Synthesis Core. MAb391 (R&D systems, Minneapolis, MN, USA) was dissolved in PBS.
Lovly C.M., McDonald N.T., Chen H., Ortiz-Cuaran S., Heukamp L.C., Yan Y., Florin A., Ozretić L., Lim D., Wang L., Chen Z., Chen X., Lu P., Paik P.K., Shen R., Jin H., Buettner R., Ansén S., Perner S., Brockmann M., Bos M., Wolf J., Gardizi M., Wright G.M., Solomon B., Russell P.A., Rogers T.M., Suehara Y., Red-Brewer M., Tieu R., de Stanchina E., Wang Q., Zhao Z., Johnson D.H., Horn L., Wong K.K., Thomas R.K., Ladanyi M, & Pao W. (2014). Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer. Nature medicine, 20(9), 1027-1034.
+ Open protocol
+ Expand
4

Preparation and Dissolution of Kinase Inhibitors

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
X-376 was prepared as described previously14 (link). Crizotinib (ChemieTek, Indianapolis, IN, USA), OSI-906 (Selleck Chemicals, Houston, TX, USA), AEW-541 (Selleck Chemicals, Houston, TX, USA), LDK-378 (Selleck Chemicals, Houston, TX, USA) and Lapatinib (Selleck Chemicals, Houston, TX, USA) were dissolved in DMSO. Erlotinib was synthesized by the Memorial Sloan-Kettering Cancer Center (MSKCC) Organic Synthesis Core. MAb391 (R&D systems, Minneapolis, MN, USA) was dissolved in PBS.
Lovly C.M., McDonald N.T., Chen H., Ortiz-Cuaran S., Heukamp L.C., Yan Y., Florin A., Ozretić L., Lim D., Wang L., Chen Z., Chen X., Lu P., Paik P.K., Shen R., Jin H., Buettner R., Ansén S., Perner S., Brockmann M., Bos M., Wolf J., Gardizi M., Wright G.M., Solomon B., Russell P.A., Rogers T.M., Suehara Y., Red-Brewer M., Tieu R., de Stanchina E., Wang Q., Zhao Z., Johnson D.H., Horn L., Wong K.K., Thomas R.K., Ladanyi M, & Pao W. (2014). Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer. Nature medicine, 20(9), 1027-1034.
+ Open protocol
+ Expand
5

Compound Acquisition for Cell Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
Vandetanib and cabozantinib were purchased from Selleckchem (Houston, TX). Crizotinib was purchased from Chemie Tek (Indianapolis, IN). AZ-23 was purchased from Axon Medchem (Groningen, The Netherlands).
Wiesner T., He J., Yelensky R., Esteve-Puig R., Botton T., Yeh I., Lipson D., Otto G., Brennan K., Murali R., Garrido M., Miller V.A., Ross J.S., Berger M.F., Sparatta A., Palmedo G., Cerroni L., Busam K.J., Kutzner H., Cronin M.T., Stephens P.J, & Bastian B.C. (2014). Kinase fusions are frequent in Spitz tumors and spitzoid melanomas. Nature communications, 5, 3116.
+ Open protocol
+ Expand
6

Xenograft Modeling of GIST Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Age and sex-matched KitV558del/+ (25 (link)), NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG), and C57BL/6J (B6) mice (Jackson Laboratory) were used. All procedures and treatments were approved by our Institutional Animal Care and Use Committee. For xenograft experiments, 106 GIST-T1, HG129, or HG209 cells in PBS were mixed 1:1 with BD Matrigel Matrix Growth Factor Reduced (BD Biosciences) and injected subcutaneously into the right flank of NSG mice. Xenograft tumors were measured using the modified ellipsoid formula (1/2 × length × width × height), and treatment was initiated when mean tumor volume reached approximately 100 mm3. Imatinib, sunitinib, and crizotinib were purchased from LC Laboratories. Imatinib (600 mg/L in drinking water), sunitinib (53.6 mg/kg daily gavage), crizotinib (60 mg/kg daily gavage), and cabozantinib (50 mg/kg daily gavage, ChemieTek) were administered. Control mice received regular drinking water and gavage vehicle.
Cohen N.A., Zeng S., Seifert A.M., Kim T.S., Sorenson E.C., Greer J.B., Beckman M.J., Santamaria-Barria J.A., Crawley M.H., Green B.L., Rossi F., Besmer P., Antonescu C.R, & DeMatteo R.P. (2015). Pharmacological inhibition of KIT activates MET signaling in gastrointestinal stromal tumors. Cancer research, 75(10), 2061-2070.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!